Foresite Capital Management Ii, Llc - Net Worth and Insider Trading
Foresite Capital Management Ii, Llc Net Worth
The estimated net worth of Foresite Capital Management Ii, Llc is at least $141 Million dollars as of 2024-08-28. Foresite Capital Management Ii, Llc is the 10% Owner of Aimmune Therapeutics Inc and owns about 4,087,900 shares of Aimmune Therapeutics Inc (AIMT) stock worth over $141 Million. Details can be seen in Foresite Capital Management Ii, Llc's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Foresite Capital Management Ii, Llc has not made any transactions after 2015-08-24 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Foresite Capital Management Ii, Llc
Foresite Capital Management Ii, Llc Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Foresite Capital Management Ii, Llc owns 3 companies in total, including 10x Genomics Inc (TXG) , Aerie Pharmaceuticals Inc (AERI) , and Aimmune Therapeutics Inc (AIMT) .
Insider Ownership Summary of Foresite Capital Management Ii, Llc
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| TXG | 10x Genomics Inc | 2020-03-04 | 10 percent owner |
| AERI | Aerie Pharmaceuticals Inc | 2016-07-22 | 10 percent owner |
| AIMT | Aimmune Therapeutics Inc | 2016-08-18 | 10 percent owner |
Foresite Capital Management Ii, Llc Latest Holdings Summary
Foresite Capital Management Ii, Llc currently owns a total of 1 stock. Foresite Capital Management Ii, Llc owns 4,087,900 shares of Aimmune Therapeutics Inc (AIMT) as of August 24, 2015, with a value of $141 Million.
Latest Holdings of Foresite Capital Management Ii, Llc
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| AIMT | Aimmune Therapeutics Inc | 2015-08-24 | 4,087,900 | 34.49 | 140,991,671 |
Holding Weightings of Foresite Capital Management Ii, Llc
Foresite Capital Management Ii, Llc Form 4 Trading Tracker
According to the SEC Form 4 filings, Foresite Capital Management Ii, Llc has made a total of 0 transactions in Aimmune Therapeutics Inc (AIMT) over the past 5 years. The most-recent trade in Aimmune Therapeutics Inc is the acquisition of 25,485 shares on August 24, 2015, which cost Foresite Capital Management Ii, Llc around $500,780.
Insider Trading History of Foresite Capital Management Ii, Llc
- 1
Foresite Capital Management Ii, Llc Trading Performance
GuruFocus tracks the stock performance after each of Foresite Capital Management Ii, Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Foresite Capital Management Ii, Llc is -12.49%. GuruFocus also compares Foresite Capital Management Ii, Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Foresite Capital Management Ii, Llc within 3 months outperforms 0 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Foresite Capital Management Ii, Llc's insider trading performs compared to the benchmark.
Performance of Foresite Capital Management Ii, Llc
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 16.57 | | | | | |
| Relative Return to S&P 500(%) | 18.49 | | | | | |
Foresite Capital Management Ii, Llc Ownership Network
Foresite Capital Management Ii, Llc Owned Company Details
What does 10x Genomics Inc do?
Who are the key executives at 10x Genomics Inc?
Foresite Capital Management Ii, Llc is the 10 percent owner of 10x Genomics Inc. Other key executives at 10x Genomics Inc include director & 10 percent owner & Chief Executive Officer Serge Saxonov , director & See Remarks Benjamin J. Hindson , and Chief Financial Officer Justin J. Mcanear .
10x Genomics Inc (TXG) Insider Trades Summary
Over the past 18 months, Foresite Capital Management Ii, Llc made no insider transaction in 10x Genomics Inc (TXG). Other recent insider transactions involving 10x Genomics Inc (TXG) include a net sale of 97,946 shares made by Serge Saxonov , a net sale of 41,247 shares made by Benjamin J. Hindson , and a net sale of 12,784 shares made by Justin J. Mcanear .
In summary, during the past 3 months, insiders sold 14,061 shares of 10x Genomics Inc (TXG) in total and bought 0 shares, with a net sale of 14,061 shares. During the past 18 months, 223,174 shares of 10x Genomics Inc (TXG) were sold and 0 shares were bought by its insiders, resulting in a net sale of 223,174 shares.
10x Genomics Inc (TXG)'s detailed insider trading history can be found in Insider Trading Tracker table.
10x Genomics Inc Insider Transactions
Foresite Capital Management Ii, Llc Mailing Address
Above is the net worth, insider trading, and ownership report for Foresite Capital Management Ii, Llc. You might contact Foresite Capital Management Ii, Llc via mailing address: 900 Larkspur Landing Circle, Suite 150, Larkspur Ca 94939.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
